Some trials in children with rhinitis and rhinoconjunctivitis
Oct 2012-Feb 2014.
Author, year
Intervention Outcome measure
Details
1. Chen
2013(1)
SLIT HDM
drops
‘rhinitis symptom
scores’. Not specified,
article in Chinese
2. Tosca
2014(2)
SLIT HDM
VAS nasal symptom
severity, VAS medication
use
3. Queirós
2013(3)
SLIT HDM
Total symptom and
medication scores for
nose/eye/bronchial
symptoms (8-item tool)
and medication score.
4. Yang
2013(4)
Untreated AR
children
AR symptom scores,
Attention-deficithyperactivity-disorder
symptom scale,
computerized
continuous performance
test (CPT) for attention
and impulsivity
5. Fuertes
2013(5)
Pollution.
Epidemiology
study
Presence
rhinoconjunctivitis
symptoms, according to
2 questions on the ISAAC
questionnaire.
Descriptive. 122 children 3-14yo:
comparison between preschool (3-6y)
and school-ago. Asthma symptom
scores (day and night), rhinitis
symptom scores and medication scores
at 6, 12 and 24mo. No difference
between age-groups in any outcome.
All reduced asthma medication.
Comparing efficacy of IT in children
with Pre-SLIT sIgE >10 kU/l (31 children
) and sIgE <10 kU/l (8 children).
Outcomes: VAS for nasal symptom
severity and drug use. Responders were
those with >6 VAS.
There was a strong relationship
between perception of AIT efficacy by
VAS and pre-SLIT serum sIgE levels (r =
0.615; p < 0.001).
DBPC, Dpt/DPT+Bact/placebo. Total
symptom and medication scores for
rhinitis/asthma, SPT, specific antibodies
IgE, IgG, IgG4 and salivary IgA baseline,
12 and 18mo.both active groups
improved symptoms.
6-15yo. 105 AR children, 29 controls, 10
ADHD children. Hyperactivity and
Impulsivity corroborated by Rating
Scale and Continuous Performance
Test.
Risk factors for inattention and
impulsivity in AR children: younger age,
male gender, higher AR symptom
scores, persistent AR, moderate/severe
AR, multiple atopic diseases, family
history of atopy, and possible
comorbidity with ADHD
6604 children. Airpollution at birth, 6
and 10y home addresses, allergic
sensitization (spIgE) association.
Questionnaire-derived annual reports
of doctor diagnosed asthma and AR,
eye and nose symptoms. In East
Germany: associations with ozone were
sign.elevated for allergic rhinitis and
eyes and nose symptom prevalence.
But not in South or N. The study did not
find consistent evidence
DBPC 476 children 6-11yo with SAR.
Significant differences between active
and placebo groups. 2 week study.
6. Storms
2013(6)
beclometasone
Average daily morning
and evening reflective
total nasal symptom
score.
Average morning and
evening instantaneous
total nasal symptom
score
7. KoinisMichell
2013(7)
8. Zicari
2013(8)
none
Rhinitis control assessment
test, nose flow guess, nasal
peak flows
upper airway compromise
Active anterior
rhinomanometry
9. Yukselen
2013(9)
SLIT or SCIT
with HDM.
Measuring nasal obstr in 53 children 410yrs with PAR. Serum resistin levels
correlated with presence of nasal
obstruction.
30 children with allergy to HDM
received DBDDPC SLIT/SCIT/placebo.
Afterwards all continued 1 year more
active Tx and placebo patients SCIT or
SLIT.
10. Anantasit
2013(10)
none
11. De Castro
2013(11)
SLIT HDM
12. Cui
2013(12)
SLIT HDM
13. Meltzer
2013(13)
Mometasone
furoate
Nasal symptoms score (4
symptoms 0-3 point),
bronchial symptom
score, medication score,
nasal and bronchial
provocation testing.
Conjunctival and nasal
provocation tests: postchallenge evaluation=
nasal symptoms (4, 3point scale), nasal
peakflow and anterior
rhinomanometry
Rhinitis Symptom Score
(4 items, 0-3scale),
Asthma Symptom Score
((4 items, 0-3scale),) and
Medication Score (MS)
Symptom scores,
medication scores ,
global evaluation of
symptoms, medication,
patients' degree of
satisfaction
Reflective AM and PM
nasal congestion scores
55 children. CPT can be an alternative
test for NPT in allergic rhinitis children
with house dust mite sensitization,
even if they do not have conjunctival
symptoms.
Real life study of 140 children 6-14yrs,
with AR/Asthma. After 3 years
significant improved RSS and ASS and
MS in active group, baseline-end, but
not in controls.
62 children 4-5yrs, 71 children 11-12yrs
randomized to SLIT or control group.
Symptom and medication scores and
global evaluation all improved after 2
years in both age-groups. 2 years after
treatment discontinuation patient
satisfaction was better in 11-12yrs.
Post-hoc evaluation of 2 studies: 6-11yo
and 3-11yo randomized to MF or
(0=none to 3=severe),
scored 2/day in diary.
(original trial primary
outcome: physician
evaluated TNSS, 4 items)
Total nasal symptom
score, individual NSS
placebo x 4weeks. Nasal congestion
scores improved.
Primary outcomes: NSS
(4 items, 0-3 score) and
QoL score. Medication
score also recorded.
Symptom and
medication scores, lung
functions, bronchial
hyperreactivity, nasal
provocation
Pediatric RQLQ and total
sympt score (nasal and
non-nasal), nasal peak
expiratory flow.
30 Chinese with PAR: The pollen blocker
more effective than the placebo (sign) in
reducing NSS and in improving QoL in adults
and children.
14. Lin
2013(14)
SLIT
15. Li 2013(15)
Blocking pollen
cream
16. Aydogan
SLIT HDM
17. Mak
2013(17)
Mometasone
vs. fluticasone
furoate
18. Ozkaya
2013(18)
None
Nasal symptom score
19. Gotoh
2012(19)
pranlukast
Nasal obstruction scores
20. Yukselen
2012(20)
None
TNSS, peak nasal
inspiratory flow, FEV1.
2013(16)
Open observations trial of 116 children
with AR. At 6mo TNSS and INSS
significantly decreased from baseline.
Suppresion of TIM-1 predicates clinical
efficacy SLIT
DBPC, 22 children 5-10yo with
perennial ACR, no asthma. No
differences in scores between groups.
94 children, 6-12yo with PAR
randomized to 4 week treatment.
Mometasone more effective than
fluticasone on TSS. But flut more
effective on non-nasal symptoms.
66 children, 7-12yo. Plasma
paraoxonase activity and plasma total
oxidant status (TOS) correlate with
disease severity in children (NSS)
10-15yo with Japanese Cedar pollinosis.
Pranlukast reduced nasal obstruction
score and ECP in nasal secretion.
24 children with AR+Asthma.
Correlations between nasal eosinophils
NIF and FEV1.
Not included: Hui 2013 (asthma trial) Li 2013 (asthma trial), kopp 2013 (no pediatric sub-group analysis), Rachelefsky
2013(21) is a review article,
1.
Chen S, Wang L, Liao F, Zeng X, Xing QB, Chen B, et al. [Efficacy of sublingual
immunotherapy with Dermatophagoides farinae drops in preschool and school-age children with
allergic asthma and allergic rhinitis]. Zhonghua er ke za zhi Chinese journal of pediatrics.
2013;51(11):831-5.
2.
Tosca M, Sivestri M, Accogli A, Rossi GA, Ciprandi G. Serum-specific IgE and allergen
immunotherapy in allergic children. Immunotherapy. 2014;6(1):29-33.
3.
Queiros MG, Silva DA, Siman IL, Ynoue LH, Araujo NS, Pereira FL, et al. Modulation of
mucosal/systemic antibody response after sublingual immunotherapy in mite-allergic children.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy
and Immunology. 2013;24(8):752-61.
4.
Yang MT, Lee WT, Liang JS, Lin YJ, Fu WM, Chen CC. Hyperactivity and Impulsivity in
Children with Untreated Allergic Rhinitis: Corroborated by Rating Scale and Continuous
Performance Test. Pediatrics and neonatology. 2013.
5.
Fuertes E, Standl M, Cyrys J, Berdel D, von Berg A, Bauer CP, et al. A longitudinal analysis of
associations between traffic-related air pollution with asthma, allergies and sensitization in the
GINIplus and LISAplus birth cohorts. PeerJ. 2013;1:e193.
6.
Storms WW, Segall N, Mansfield LE, Amar NJ, Kelley L, Ding Y, et al. Efficacy and safety of
beclomethasone dipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis.
Ann Allergy Asthma Immunol. 2013;111(5):408-14 e1.
7.
Koinis-Mitchell D, Esteban C, Kopel SJ, Jandasek B, Dansereau K, Fritz GK, et al. Perceptual
accuracy of upper airway compromise in children: Clinical relevance and future directions for
research. Allergy & rhinology. 2013;4(2):e54-62.
8.
Zicari AM, Occasi F, Marcelli AC, Lollobrigida V, Carbone MP, Galandrini R, et al. Assessing
the relationship between serum resistin and nasal obstruction in children with allergic rhinitis.
American journal of rhinology & allergy. 2013;27(5):e127-30.
9.
Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Two year follow-up of clinical
and inflammation parameters in children monosensitized to mites undergoing subcutaneous and
sublingual immunotherapy. Asian Pacific journal of allergy and immunology / launched by the
Allergy and Immunology Society of Thailand. 2013;31(3):233-41.
10.
Anantasit N, Vilaiyuk S, Kamchaisatian W, Supakornthanasarn W, Sasisakulporn C,
Teawsomboonkit W, et al. Comparison of conjunctival and nasal provocation tests in allergic
rhinitis children with Dermatophagoides pteronyssinus sensitization. Asian Pacific journal of
allergy and immunology / launched by the Allergy and Immunology Society of Thailand.
2013;31(3):227-32.
11.
De Castro G, Zicari AM, Indinnimeo L, Tancredi G, di Coste A, Occasi F, et al. Efficacy of
sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life. European
review for medical and pharmacological sciences. 2013;17(16):2225-31.
12.
Cui L, Wang ZN, Xu ZQ, Xia ZF. [Efficacy and safety of sublingual immunotherapy of allergic
rhinitis in children between 4 and 5 years age group and 11 and 12 years age group]. Zhonghua er
bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery.
2013;48(1):17-21.
13.
Meltzer EO, Baena-Cagnani CE, Gates D, Teper A. Relieving nasal congestion in children
with seasonal and perennial allergic rhinitis: efficacy and safety studies of mometasone furoate
nasal spray. The World Allergy Organization journal. 2013;6(1):5.
14.
Lin Z, Zhou L, Luo X, Xia W, Chen D, Xu R, et al. Suppression of TIM-1 predicates clinical
efficacy of sublingual immunotherapy for allergic rhinitis in children. International journal of
pediatric otorhinolaryngology. 2013;77(8):1345-9.
15.
Li Y, Wang D, Liu Q, Liu J. Randomized double-blind placebo-controlled crossover study of
efficacy of pollen blocker cream for perennial allergic rhinitis. American journal of rhinology &
allergy. 2013;27(4):299-303.
16.
Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, et al. Sublingual
immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites:
a double-blind-placebo-controlled randomised trial. Respiratory medicine. 2013;107(9):1322-9.
17.
Mak KK, Ku MS, Lu KH, Sun HL, Lue KH. Comparison of mometasone furoate monohydrate
(Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mitesensitive children with perennial allergic rhinitis. Pediatrics and neonatology. 2013;54(4):239-45.
18.
Ozkaya E, Akduman H, Erenberk U, Demir A, Dundaroz MR. Plasma paraoxonase activity
and oxidative stress and their relationship to disease severity in children with allergic rhinitis.
American journal of rhinology & allergy. 2013;27(1):13-7.
19.
Gotoh M, Okubo K, Hashiguchi K, Wakabayashi K, Kanzaki S, Tanaka N, et al. Noninvasive
biological evaluation of response to pranlukast treatment in pediatric patients with Japanese cedar
pollinosis. Allergy Asthma Proc. 2012;33(6):459-66.
20.
Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Correlation between nasal
eosinophils and nasal airflows in children with asthma and/or rhinitis monosensitised to house
dust mites. Allergologia et immunopathologia. 2012.
21.
Rachelefsky G, Farrar JR. A control model to evaluate pharmacotherapy for allergic rhinitis
in children. JAMA pediatrics. 2013;167(4):380-6.